All In Biotech

Drug Trial Radar · NCT07770828

Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD

A Phase 3 Registrational Study To Assess The Efficacy, Safety, And Tolerability Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 237 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

237

Planned (sponsor's estimate)

Start

Aug 11, 2026

Primary completion

Jul 30, 2028

Study completion Jul 30, 2031

Sponsor

Lead sponsor
OcugenIndustry
Sponsor type
Industry
First posted
Aug 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm

Conditions

  • Dry Age-related Macular Degeneration

Interventions

  • OCU410Biological

    Subretinal Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of change (slope) of square root-transformed GA lesion area from baseline to Month 12Time frame: Month 12

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • associated Retina Consultants

    Phoenix, Arizona · Not yet recruiting

  • Erie Retina Research

    Erie, Pennsylvania · Not yet recruiting

  • Valley Retina Institute

    McAllen, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.